Nov. 17, 2009 (PR Newswire) --
MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.
Conference Call Information
Domestic callers: 1-800-776-0853
International callers: 1-913-312-0980
Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT:
VIVUS, Inc. Investor Relations: The Trout Group
Timothy E. Morris Brian Korb
Chief Financial Officer 646-378-2923
650-934-5200
Media Relations: Pure Communications, Inc.
Dan Budwick
973-271-6085
SOURCE VIVUS, Inc.
